Be Ready to Expedite Treatment for Malignant Hyperthermia
February 2018
Hospitals are striving to meet expectations for treating malignant hyperthermia.
About one in 2,000 people are at risk for malignant hyperthermia from exposure to anesthetic gases (desflurane, etc) or succinylcholine.
These patients can have muscle rigidity, hyperthermia, tachycardia, or hypercapnia from uncontrolled calcium release in the muscle...which can lead to rhabdomyolysis, arrhythmias, acute kidney injury, and death.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote